FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740373339> ?p ?o ?g. }

• W2740373339 endingPage "3730" @default.
• W2740373339 startingPage "3730" @default.
• W2740373339 abstract "Abstract PURPOSE. Tumor-Treating Fields (TTFields) is an FDA-approved treatment approach for patients with both newly-diagnosed and recurrent glioblastoma. The main purpose of the present study was to explore if amino acid positron emission tomography (PET) is able to detect an early, objective metabolic tumor response during the first months of TTFields therapy. METHODS. Patients with MRI signs of recurrent glioblastoma eligible for TTFields along with maintenance temozolomide were recruited for PET scanning with alpha[C-11]-methyl-L-tryptophan (AMT) at baseline (before start of TTFields application) and up to 3 months later. Serial MRIs were also performed in 1-2 months intervals. AMT accumulation in the MRI-detected tumor mass was measured by standardized uptake values (SUVs), and PET-based tumor volumes were also calculated. Interval changes of these PET variables were compared to changes in areas of MRI enhancement. RESULTS. Out of 7 recruited patients, 5 showed appropriate compliance (&gt;75%) with the device and underwent follow-up PET. Four of the 5 patients showed a clear metabolic response during TTF treatment on PET imaging. Two patients, who received TTFields treatment only (in addition to maintenance temozolomide), showed 25% and 100% decrease of PET-based tumor volumes, respectively. MRI was stable (patient #1) or showed increasing contrast enhancement (#2) during the same period. In this latter patient, TTFields was continued with bevacizumab treatment, leading to decreased contrast enhancement and further decrease of AMT uptake on a second follow-up PET. In two other patients (#3 and #4), TTFields were combined with bevacizumab rescue treatment. Patient #3 showed a markedly decreased tumoral AMT uptake and metabolic volume along with stable MRI enhancement. Patient #4 showed interval decrease of tryptophan PET uptake 2 months after initiation of TTFields therapy. Finally, patient #5 showed an interval expansion of the PET-based tumor volume along with MRI progression during a 2-month follow-up despite TTFields combined with bevacizumab and carboplatin. CONCLUSIONS. This is the first study to demonstrate an objective metabolic response of recurrent glioblastoma within 1.5-3 months after initiation of TTFields. The data suggest that amino acid PET can identify early responders to TTFields therapy. Citation Format: Sandeep Mittal, Geoffrey R. Barger, Edit Bosnyák, Varun B. Shah, Csaba Juhász. Early metabolic response to tumor-treating fields in patients with recurrent glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3730. doi:10.1158/1538-7445.AM2017-3730" @default.
• W2740373339 created "2017-08-08" @default.
• W2740373339 creator A5018555284 @default.
• W2740373339 creator A5021942648 @default.
• W2740373339 creator A5057792364 @default.
• W2740373339 creator A5074904985 @default.
• W2740373339 creator A5079224829 @default.
• W2740373339 date "2017-07-01" @default.
• W2740373339 modified "2023-09-26" @default.
• W2740373339 title "Abstract 3730: Early metabolic response to tumor-treating fields in patients with recurrent glioblastoma" @default.
• W2740373339 doi "https://doi.org/10.1158/1538-7445.am2017-3730" @default.
• W2740373339 hasPublicationYear "2017" @default.
• W2740373339 type Work @default.
• W2740373339 sameAs 2740373339 @default.
• W2740373339 citedByCount "3" @default.
• W2740373339 countsByYear W27403733392018 @default.
• W2740373339 countsByYear W27403733392019 @default.
• W2740373339 countsByYear W27403733392020 @default.
• W2740373339 crossrefType "journal-article" @default.
• W2740373339 hasAuthorship W2740373339A5018555284 @default.
• W2740373339 hasAuthorship W2740373339A5021942648 @default.
• W2740373339 hasAuthorship W2740373339A5057792364 @default.
• W2740373339 hasAuthorship W2740373339A5074904985 @default.
• W2740373339 hasAuthorship W2740373339A5079224829 @default.
• W2740373339 hasConcept C126322002 @default.
• W2740373339 hasConcept C126838900 @default.
• W2740373339 hasConcept C143998085 @default.
• W2740373339 hasConcept C2775842073 @default.
• W2740373339 hasConcept C2776194525 @default.
• W2740373339 hasConcept C2776694085 @default.
• W2740373339 hasConcept C2777389519 @default.
• W2740373339 hasConcept C2777802072 @default.
• W2740373339 hasConcept C2989005 @default.
• W2740373339 hasConcept C502942594 @default.
• W2740373339 hasConcept C71924100 @default.
• W2740373339 hasConceptScore W2740373339C126322002 @default.
• W2740373339 hasConceptScore W2740373339C126838900 @default.
• W2740373339 hasConceptScore W2740373339C143998085 @default.
• W2740373339 hasConceptScore W2740373339C2775842073 @default.
• W2740373339 hasConceptScore W2740373339C2776194525 @default.
• W2740373339 hasConceptScore W2740373339C2776694085 @default.
• W2740373339 hasConceptScore W2740373339C2777389519 @default.
• W2740373339 hasConceptScore W2740373339C2777802072 @default.
• W2740373339 hasConceptScore W2740373339C2989005 @default.
• W2740373339 hasConceptScore W2740373339C502942594 @default.
• W2740373339 hasConceptScore W2740373339C71924100 @default.
• W2740373339 hasIssue "13_Supplement" @default.
• W2740373339 hasLocation W27403733391 @default.
• W2740373339 hasOpenAccess W2740373339 @default.
• W2740373339 hasPrimaryLocation W27403733391 @default.
• W2740373339 hasRelatedWork W2079027559 @default.
• W2740373339 hasRelatedWork W2119633088 @default.
• W2740373339 hasRelatedWork W2123760882 @default.
• W2740373339 hasRelatedWork W2315241269 @default.
• W2740373339 hasRelatedWork W2767887294 @default.
• W2740373339 hasRelatedWork W4200432308 @default.
• W2740373339 hasRelatedWork W4240152538 @default.
• W2740373339 hasRelatedWork W4255082608 @default.
• W2740373339 hasRelatedWork W4361935923 @default.
• W2740373339 hasRelatedWork W4362407940 @default.
• W2740373339 hasVolume "77" @default.
• W2740373339 isParatext "false" @default.
• W2740373339 isRetracted "false" @default.
• W2740373339 magId "2740373339" @default.
• W2740373339 workType "article" @default.